Health Canada has eliminated Phase III trial requirements for biosimilars, prioritizing analytical studies over large clinical trials to accelerate market access and reduce costs.
In a landmark regulatory shift, Health Canada has officially removed the requirement for biosimilar drug manufacturers to conduct Phase III clinical trials as a condition for market approval. The final, updated Guidance on Information and Submission Requirements for Biosimilar Biologic Drugs was published on 19 May 2026, following a consultation period that began with a draft release on the proposed revisions on 10 June 2025 [1].
The new guidance represents a fundamental change in how biosimilar drugs—biologically manufactured copies of innovative biological medicines—are evaluated for safety and efficacy in Canada. Under the previous framework, sponsors were generally required to submit comparative clinical data, including a Phase III clinical study demonstrating the absence of clinically meaningful differences in efficacy, safety, and immunogenicity between the biosimilar candidate and its Canadian Reference Biologic Drug (CRBD). Phase III trials are notoriously costly and time-consuming, with a US study finding an average cost of US$20.8 million and a median treatment duration of 52 weeks.
Shift to analytical evidence
The revised guidance now states that comparative clinical efficacy studies—i.e., Phase III trials—'are not typically required’. Instead, the clinical studies needed to support authorization are ‘generally limited to a comparative pharmacokinetic trial’ designed to demonstrate pharmacokinetic equivalence, while also collecting data on safety and immunogenicity.
Health Canada now emphasizes that ‘structural and functional studies are generally considered more sensitive than clinical studies for detecting differences between a biosimilar candidate and its CRBD’. Sponsors are expected to establish similarity primarily through comprehensive comparative analytical studies, including physicochemical, functional, and stability testing. The guidance explicitly states that ‘similarity should be deduced primarily from comprehensive and appropriately designed comparative analytical studies’.
Additional key changes
The updated guidance also removes the previous requirement for sponsors to provide a detailed scientific rationale justifying approval for each individual indication claimed for a biosimilar. Health Canada now provides that where a biosimilar candidate has been shown to be highly similar to the reference drug and can deliver the same dosage, ‘all the indications granted to the CRBD can be applied to the biosimilar candidate without further justification’.
For short polypeptide drugs, the classification as either a biosimilar or a generic drug depends on the manufacturing method—recombinant DNA procedures qualify as biosimilar, while chemical synthesis may be eligible for the generic pathway.
Alignment with international trends
The changes align Canada with regulatory modernization efforts underway in the United States [2] and Europe [3]. Health Canada received comments from 15 stakeholders during the consultation period, representing biopharmaceutical companies, industry associations, patient organizations, and the general public.
The new guidance is part of a broader ‘Red Tape Review’ initiative launched by the Government of Canada in 2025, aimed at reducing regulatory burdens, streamlining processes, and improving efficiency across federal departments. While guidance documents do not carry the force of law, Health Canada generally applies them when evaluating drug submissions.
Implications for patients and industry
Industry observers note that eliminating the Phase III requirement may accelerate biosimilar development and market entry in Canada, potentially leading to faster patient access and lower costs. However, the shift may also trigger earlier litigation under the Patented Medicines (Notice of Compliance) Regulations, as biosimilars reach the market more quickly.
The full guidance document is available on Health Canada's official website.
Related article
FDA issues new guidance on biosimilar development and the BPCI Act
|
LATIN AMERICAN FORUM
The objective of GaBI’s Latin American Forum is to provide you with all the latest news and updates on developments of generic and biosimilar medicines in Latin America in Spanish. View the latest headline article: Adopción de biosimilares en Chile: ¿Por qué se demora? Browse the news in the Latin American Forum! Register to receive the GaBI Latin American Forum newsletter. Inform colleagues and friends of this new initiative.
FORO LATINOAMERICANOd
El objetivo del Foro Latinoamericano de GaBI es brindarle las últimas noticias y actualizaciones sobre desarrollos de medicamentos genéricos y biosimilares en América Latina en español. Ver el último artículo de cabecera: Adopción de biosimilares en Chile: ¿Por qué se demora? !Explore las noticias en el Foro Latinoamericano! Regístrese para recibir el boletín informativo GaBI Foro Latinoamericano. Informe a colegas y amigos sobre esta nueva iniciativa.
|
References
1. GaBI Online - Generics and Biosimilars Initiative. Canada poised to remove requirement for Phase III trials for biosimilars [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2026 Jun 22]. Available from: www.gabionline.net/guidelines/canada-poised-to-remove-requirement-for-phase-iii-trials-for-biosimilars
2. GaBI Online - Generics and Biosimilars Initiative. FDA updates draft biosimilar guidance, signalling greater flexibility for developers [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2026 Jun 22]. Available from: www.gabionline.net/guidelines/fda-updates-draft-biosimilar-guidance-signalling-greater-flexibility-for-developers
3. GaBI Online - Generics and Biosimilars Initiative. EMA adopts landmark reflection paper on tailored clinical approach for biosimilars [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2026 Jun 22]. Available from: www.gabionline.net/guidelines/ema-adopts-landmark-reflection-paper-on-tailored-clinical-approach-for-biosimilars
Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.
Copyright – Unless otherwise stated all contents of this website are © 2026 Pro Pharma Communications International. All Rights Reserved.
0
Post your comment